Browsing Tag
Tirzepatide
32 posts
Vanda Pharmaceuticals (VNDA) bets on GLP-1 adherence gap with new Nereus vomiting-prevention study
Vanda Pharmaceuticals has launched the Thetis study to test Nereus in GLP-1-related vomiting. Read what this means for obesity drug adherence and VNDA.
One pen, four doses, one month: Eli Lilly brings Zepbound KwikPen to Ro’s telehealth platform at $299
Eli Lilly (LLY) partners with Ro to launch the FDA-approved Zepbound KwikPen nationwide. What the $299 self-pay device means for the GLP-1 race. Read more.
Why Eli Lilly’s Zepbound just tightened its grip on the obesity drug market in 2026
Find out how Eli Lilly and Company is strengthening Zepbound’s market dominance with a multi-dose KwikPen and reshaping obesity drug access in 2026.
Lilly’s oral GLP-1 orforglipron sustains weight loss after injectables in pivotal Phase 3 trial
Lilly’s orforglipron helped patients maintain weight loss after injectable GLP-1s in a Phase 3 trial. Find out how this could reshape obesity treatment paths.
Can OrsoBio’s TLC-6740 combination data reopen the race for post-GLP obesity differentiation?
OrsoBio’s TLC-6740 combo data hints at a new way to extend GLP-1 weight loss without higher doses. Read what this means for obesity drug development.
Novo Nordisk’s amycretin delivers 14.5% weight loss in type 2 diabetes trial: A dual-agonist breakthrough?
Novo Nordisk’s amycretin delivers up to 14.5% weight loss in type 2 diabetes trial. Explore the trial data and what’s next in the GLP‑1 drug race.
Is the next wave of obesity drugs moving beyond GLP-1? What Palatin, Rhythm, and Zealand are betting on
Explore how Palatin Technologies, Rhythm Pharmaceuticals, and Zealand Pharma are shifting obesity drug development beyond GLP-1 into MC4R and amylin pathways. Read on.
Zepbound vs Wegovy: How dosing, dual agonists, and payer dynamics are redrawing market lines
Zepbound and Wegovy are reshaping obesity drug competition—see how dosing, dual-agonist design, and payer rules define the next pharma showdown.
Can high-dose GLP-1 therapies reshape obesity care—or are we nearing the biological ceiling?
Are high-dose GLP-1 drugs like Wegovy 7.2mg and Zepbound 15mg unlocking better weight loss—or just more side effects? Here’s what the latest data suggests.
Are compounded weight-loss drugs the next opioid crisis? Inside the unregulated boom of off-label GLP-1s
Are GLP-1 weight-loss drugs like semaglutide fueling a new safety crisis? Explore the unregulated boom in compounded injections and FDA’s crackdown.